Blab Business
HeartSciences Files 10-K and Announces Proposed Merger with Fortitude Mining
On July 23, 2026, HeartSciences Inc. (Nasdaq: HSCS; HSCSW) filed its Form 10‑K for the fiscal year that ended April 30, 2026. The filing, available on the SEC’s EDGAR database and the company’s website, is the most recent public disclosure from the health‑tech firm.
In the same release, the company announced that it will soon file a preliminary proxy statement with the SEC to cover a proposed business combination with Fortitude Mining Holdings, Inc. Fortitude is a vertically integrated venture‑mining platform that operates in the Proof‑of‑Work (PoW) ecosystem, anchored around the privacy‑focused cryptocurrency Zcash. The mining firm is wholly owned by Digital Currency Group (DCG), a U.S. investment firm that concentrates on digital‑currency markets.
HeartSciences’ CEO, Andrew Simpson, called fiscal 2026 a "landmark year" for the company. He highlighted the launch of the MyoVista Insights platform—a device‑agnostic AI‑ECG management system—and the beginning of a transition to mainstream commercial revenue. Simpson added that the proposed merger with Fortitude represents a significant value‑creation opportunity for shareholders, allowing continued ownership in a revenue‑generating business backed by an established investor while enabling the MyoVista platform to advance with greater focus.
The company said it will issue a fiscal 2026 earnings release and a business update early next week after the proxy statement is filed. The proxy will set out the terms of the proposed transaction in detail.
Fortitude’s business model blends self‑mining operations with an owned data‑center footprint, a diversified power portfolio secured by long‑term contracts, and disciplined capital allocation. Its leadership team includes operators, capital‑markets professionals, and digital‑asset specialists who have experience identifying and scaling high‑conviction opportunities in emerging PoW ecosystems.
HeartSciences’ MyoVista Insights platform is designed to improve clinical efficiency and decision‑making. The MyoVista wavECG device delivers conventional ECG functionality while supporting on‑device AI‑enabled solutions.
The press release contains forward‑looking statements that highlight risks associated with the proposed transaction. These risks include the possibility that the transaction may not be completed on the anticipated timeline or at all, the need to satisfy closing conditions such as shareholder approval, and market or macroeconomic conditions that could adversely affect either company. Other risks noted relate to the volatility of Zcash and other cryptocurrencies, legal, commercial, regulatory and technical uncertainty surrounding digital assets, and integration challenges that could arise after a merger.
HeartSciences urged shareholders to review the forthcoming proxy materials, which will be mailed to eligible shareholders once the definitive proxy statement is filed. The company also provided contact information for its investor‑relations team.
The proposed merger would place Fortitude on the Nasdaq through an all‑stock transaction with HeartSciences, giving the mining platform a public‑market presence without a traditional initial public offering.
The filing and the announced transaction are the most recent public disclosures from HeartSciences. The company’s next public filings will include the fiscal 2026 earnings release, the business update, and the definitive proxy statement for the proposed merger.
If completed, the transaction would combine a healthcare‑technology company focused on AI‑enhanced ECGs with a digital‑asset mining platform that operates in a privacy‑preserving PoW ecosystem. The combination is intended to provide shareholders with continued ownership in a revenue‑generating business backed by an established investor while allowing HeartSciences’ AI‑ECG technology to advance.
HeartSciences’ 10‑K filing, the proxy statement, and the earnings release are all publicly available through the SEC’s EDGAR database and the company’s website. Shareholders and market participants should monitor the company’s announcements for updates on the transaction timeline and any regulatory approvals required.
The company’s next steps include filing the definitive proxy statement, holding a shareholder vote on the proposed merger, and issuing the fiscal 2026 earnings release and business update. The outcome of these actions will determine whether the merger proceeds and how it will impact the company’s strategic direction and shareholder value.
In the same release, the company announced that it will soon file a preliminary proxy statement with the SEC to cover a proposed business combination with Fortitude Mining Holdings, Inc. Fortitude is a vertically integrated venture‑mining platform that operates in the Proof‑of‑Work (PoW) ecosystem, anchored around the privacy‑focused cryptocurrency Zcash. The mining firm is wholly owned by Digital Currency Group (DCG), a U.S. investment firm that concentrates on digital‑currency markets.
HeartSciences’ CEO, Andrew Simpson, called fiscal 2026 a "landmark year" for the company. He highlighted the launch of the MyoVista Insights platform—a device‑agnostic AI‑ECG management system—and the beginning of a transition to mainstream commercial revenue. Simpson added that the proposed merger with Fortitude represents a significant value‑creation opportunity for shareholders, allowing continued ownership in a revenue‑generating business backed by an established investor while enabling the MyoVista platform to advance with greater focus.
The company said it will issue a fiscal 2026 earnings release and a business update early next week after the proxy statement is filed. The proxy will set out the terms of the proposed transaction in detail.
Fortitude’s business model blends self‑mining operations with an owned data‑center footprint, a diversified power portfolio secured by long‑term contracts, and disciplined capital allocation. Its leadership team includes operators, capital‑markets professionals, and digital‑asset specialists who have experience identifying and scaling high‑conviction opportunities in emerging PoW ecosystems.
HeartSciences’ MyoVista Insights platform is designed to improve clinical efficiency and decision‑making. The MyoVista wavECG device delivers conventional ECG functionality while supporting on‑device AI‑enabled solutions.
The press release contains forward‑looking statements that highlight risks associated with the proposed transaction. These risks include the possibility that the transaction may not be completed on the anticipated timeline or at all, the need to satisfy closing conditions such as shareholder approval, and market or macroeconomic conditions that could adversely affect either company. Other risks noted relate to the volatility of Zcash and other cryptocurrencies, legal, commercial, regulatory and technical uncertainty surrounding digital assets, and integration challenges that could arise after a merger.
HeartSciences urged shareholders to review the forthcoming proxy materials, which will be mailed to eligible shareholders once the definitive proxy statement is filed. The company also provided contact information for its investor‑relations team.
The proposed merger would place Fortitude on the Nasdaq through an all‑stock transaction with HeartSciences, giving the mining platform a public‑market presence without a traditional initial public offering.
The filing and the announced transaction are the most recent public disclosures from HeartSciences. The company’s next public filings will include the fiscal 2026 earnings release, the business update, and the definitive proxy statement for the proposed merger.
If completed, the transaction would combine a healthcare‑technology company focused on AI‑enhanced ECGs with a digital‑asset mining platform that operates in a privacy‑preserving PoW ecosystem. The combination is intended to provide shareholders with continued ownership in a revenue‑generating business backed by an established investor while allowing HeartSciences’ AI‑ECG technology to advance.
HeartSciences’ 10‑K filing, the proxy statement, and the earnings release are all publicly available through the SEC’s EDGAR database and the company’s website. Shareholders and market participants should monitor the company’s announcements for updates on the transaction timeline and any regulatory approvals required.
The company’s next steps include filing the definitive proxy statement, holding a shareholder vote on the proposed merger, and issuing the fiscal 2026 earnings release and business update. The outcome of these actions will determine whether the merger proceeds and how it will impact the company’s strategic direction and shareholder value.
